Terran Biosciences, a neurology and psychiatry-focused startup, has announced the publication of patent applications under the Patent Cooperation Treaty (PCT) for its novel prodrugs of DMT, 5-MeO-DMT and MDMA. Claim of superior pharmacokinetics The company believes the prodrugs have superior pharmacokinetic profiles compared to the unmodified forms of these Schedule I substances. Additionally, it believes…